Key facts
- Olaris’s last known valuation is $70.0M (Apr 2025).
- It has raised $29.0M; the latest was Later Stage VC ($15.0M) in Apr 2025.
- Notable investors include Alumni Ventures, Harvard Innovation Launch Lab, Labcorp Venture Fund, Northpoint Capital Group, U.S. Boston Growth Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Olaris
- ·The full record, as it builds
Funding rounds
No funding rounds for Olaris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Olaris
Developer of a precision diagnostics platform designed to identify biomarkers of treatment response. The company uses metabolite profiling and customized machine learning algorithms to determine therapy response and associated outcomes, enabling biopharmaceutical companies to improve treatment efficacy and reduce adverse events.
- Sector
- Healthcare
- HQ
- Framingham, MA, United States
- Founded
- 2014
- Employees
- 17
- Website
- myolaris.com/
- Ownership
- Privately Held (backing)
Olaris doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Olaris shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Olaris in its N-PORT filings yet. We sweep new filings monthly.